Home/Pipeline/MediPrint Lens (Glaucoma)

MediPrint Lens (Glaucoma)

Glaucoma

Phase 2bActive

Key Facts

Indication

Glaucoma

Phase

Phase 2b

Status

Active

Company

MediPrint Ophthalmics

About MediPrint Ophthalmics

MediPrint Ophthalmics is a private, clinical-stage biotech company addressing significant unmet needs in ophthalmology through its proprietary MediPrint™ contact lens drug delivery platform. The company has completed a Phase 2a study and is advancing its lead glaucoma program into Phase 2b, with a pipeline targeting multi-billion dollar markets. With a clear path to Phase 3 data and a focus on non-invasive, patient-friendly therapies, MediPrint aims to establish a new standard of care in ocular drug delivery.

View full company profile

Therapeutic Areas

Glaucoma Dry Eye Disease Ocular Allergy

Other Glaucoma Drugs

Drug	Company	Phase	Status
PREZIA Glaucoma Implant	PolyActiva	Preclinical	Active
MIGS Device System	Micropoint Biotechnologies	Commercial	Market approved in China
INM-088	InMed Pharmaceuticals	Preclinical	Active
OT-401	Ocumension Therapeutics	Phase 2	Active
ANX007	Annexon Biosciences	Phase 2	Active
PER-001	Perfuse Therapeutics	Phase 2	Active
hOTX2	BrainEver	Discovery	Active
Glaucoma Treatment	BVI Medical	Commercial	Active
Glaucoma Program	Broadwing Bio	Pre-clinical	Active
MSC Exosomal Eye Serum	Vitti Labs	Pre-clinical	Active
BTQ1902	Betaliq	Phase 2	Active
TODDD™ Platform	Amorphex Therapeutics	Pre-clinical	Active